Gelesis
Gelesis develops therapies for GI-related chronic diseases using superabsorbent hydrogels that mimic raw vegetables and are administered in capsules. Their FDA-cleared product, Plenity, is used for weight management and they are exploring treatments for Type 2 Diabetes, NAFLD/NASH, and Functional Constipation.
Services
Gelesis develops therapies for gastrointestinal (GI) related chronic diseases, primarily focusing on weight management and other metabolic disorders. They utilize superabsorbent hydrogels to mimic the properties of raw vegetables, which are administered in capsule form. Their flagship product, Plenity, is FDA-cleared and indicated for weight management in adults with a BMI of 25 to 40 kg/m², combined with diet and exercise.
Products
Gelesis’ primary product, Plenity, is designed to aid in weight management. It is indicated for use in adults with a BMI between 25 and 40 kg/m² and acts by increasing the volume and firmness of ingested foods while reducing their caloric density. Plenity is administered orally and works locally within the stomach and intestines. Gelesis also has several potential therapies in development, targeting conditions such as Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Technology
Gelesis’ proprietary technology employs superabsorbent hydrogels created from naturally-derived building blocks, specifically modified cellulose and citric acid. These hydrogels mimic the mechanical properties of raw vegetables, designed to increase food volume and firmness without adding calories. They are cross-linked to form a 3D structure, which degrades naturally in the large intestine. The hydrogels are orally administered and maintain their properties through the small intestine. They are being researched for their potential to improve gut barrier dysfunction and related diseases.
Research and Development
Gelesis is actively involved in developing innovative therapies using their hydrogel technology. They have received a $1.4 million grant to advance a new polymeric platform. The hydrogel technology is being studied for its potential effects on Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), Functional Constipation, and gut barrier dysfunction. Gelesis’ comprehensive research aims to treat obesity and other GI-related chronic diseases by altering the mechanical properties and composition of GI content.
Global Presence
Gelesis extends its global reach with a presence in Italy through Gelesis SRL. This international footprint supports their mission to provide innovative solutions for weight management and GI-related chronic diseases globally. Their technology, inspired by nature and validated by scientific research, aims to address the growing need for effective therapies in metabolic and gastrointestinal health.